As­traZeneca rolls out 'un­prece­dent­ed' 3-year sur­vival da­ta for PD-L1/CT­LA4 com­bo in liv­er can­cer

Months af­ter As­traZeneca tout­ed a ma­jor over­all sur­vival win for its Imfinzi/treme­li­mum­ab com­bo, the com­pa­ny is ready to spell out what it calls “un­prece­dent­ed” re­sults.

In a Phase III study dubbed HI­MALAYA, 1,324 pa­tients with un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma were ran­dom­ized in­to three co­horts: one re­ceiv­ing the STRIDE reg­i­men — a sin­gle prim­ing dose of the CT­LA4 drug treme­li­mum­ab and then PD-L1 in­hibitor Imfinzi every four weeks — an­oth­er tak­ing Imfinzi alone and the third re­ceiv­ing Nex­avar (so­rafenib), the stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER